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Incorrect disclosure verbiage resulting from an interactive online submission form was discovered in Goldberg et al 2017. Thanks to Dr. Joseph F. Goldberg for discovering the error. The error relates to the wording of the disclosure in the original article, which incorrectly suggests that the authors received "personal fees" from Sunovion and from other companies, instead of research grants, speaker fees, and consulting fees.
The corrected disclosure statement can be found here. The error is the complete responsibility of the coauthors.
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